[ad_1]
CTI BioPharma Corp (NASDAQ:CTIC) shares were up 7.8% on Friday . The stock traded as high as $1.13 and last traded at $1.10. Approximately 901,718 shares traded hands during trading, an increase of 139% from the average daily volume of 378,032 shares. The stock had previously closed at $1.02.
Several research analysts recently weighed in on CTIC shares. Oppenheimer set a $4.00 price target on CTI BioPharma and gave the company a “buy” rating in a research report on Friday, December 28th. ValuEngine upgraded CTI BioPharma from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. CTI BioPharma has an average rating of “Buy” and a consensus target price of $6.00.
The company has a quick ratio of 3.58, a current ratio of 3.58 and a debt-to-equity ratio of 0.20.
Several institutional investors have recently bought and sold shares of the company. Two Sigma Advisers LP increased its position in shares of CTI BioPharma by 14.0% in the fourth quarter. Two Sigma Advisers LP now owns 115,483 shares of the biopharmaceutical company’s stock valued at $85,000 after buying an additional 14,200 shares in the last quarter. Stonepine Capital Management LLC increased its position in shares of CTI BioPharma by 8.0% in the fourth quarter. Stonepine Capital Management LLC now owns 5,726,579 shares of the biopharmaceutical company’s stock valued at $4,201,000 after buying an additional 424,516 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of CTI BioPharma in the fourth quarter valued at approximately $35,000. Rhumbline Advisers increased its position in shares of CTI BioPharma by 45.4% in the fourth quarter. Rhumbline Advisers now owns 66,079 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 20,630 shares in the last quarter. Finally, Fosun International Ltd purchased a new stake in shares of CTI BioPharma in the fourth quarter valued at approximately $253,000. Institutional investors and hedge funds own 61.07% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “CTI BioPharma (CTIC) Trading Up 7.8%” was originally reported by Fairfield Current and is owned by of Fairfield Current. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.fairfieldcurrent.com/news/2019/03/03/cti-biopharma-ctic-trading-up-7-8.html.
About CTI BioPharma (NASDAQ:CTIC)
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis.
Featured Article: Exchange-Traded Funds (ETFs)
Receive News & Ratings for CTI BioPharma Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for CTI BioPharma and related companies with MarketBeat.com’s FREE daily email newsletter.
[ad_2]
Source link Google News
